Publications

Sort by: Date | Author | Title

Zinzani, P. L., d'Amore, F., Bombardieri, E., Brammer, C., Codina, J. G., Illidge, T., Jurczak, W., Linkesch, W., Morschhauser, F., Vandenberghe, E. & Van Hoof, A. (2008). Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. European Journal of Cancer, 44(3), 366-73. https://doi.org/10.1016/j.ejca.2007.12.008
Zinzani, P., Coiffier, B., Radford, J., Caballero, D., Fields, P., Chamuleau, M., D'Amore, F. A., Haioun, C., Thieblemont, C., Barca, E., Garcia, C., Johnson, PW., Van Imhoff, G., Saunders, A., Dwyer, K. & Morschhauser, F. (2014). A phase II open-label, multi-center study of anti-CCR4 monoclonal antibody mogamulizumab (KW-0761) in patients with previously treated peripheral t-cell lymphoma (PTCL). Blood, 124(21).
Zinzani, P. L., Karlin, L., Radford, J., Caballero, D., Fields, P., Chamuleau, M. E. D., d'Amore, F., Haioun, C., Thieblemont, C., González-Barca, E., Grande García, C., Johnson, P. W., van Imhoff, G. W., Ng, T., Dwyer, K. & Morschhauser, F. (2016). European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. Haematologica, 101(10), e407-e410. https://doi.org/10.3324/haematol.2016.146977
Wulf, G. G., Altmann, B., Ziepert, M., D’Amore, F., Held, G., Greil, R., Tournilhac, O., Relander, T., Viardot, A., Wilhelm, M., Wilhelm, C., Pezzutto, A., Zijlstra, J. M., Neste, E. V. D., Lugtenburg, P. J., Doorduijn, J. K., Gelder, M. V., van Imhoff, G. W., Zettl, F. ... ACT-2 study investigators (2021). Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia, 35(1), 143-155. https://doi.org/10.1038/s41375-020-0838-5
Wästerlid, T., Brown, P. D. N., Hagberg, O., Hagberg, H., Pedersen, LM., D'Amore, F. A. & Jerkeman, M. (2013). Impact of chemotherapy regimen and rituximab in adult Burkitt Lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Annals of Oncology, 24(7), 1879-1886.
Vase, M. Ø., Maksten, E. F., Bendix, K., Hamilton-Dutoit, S. J., Andersen, C., Møller, M. B., Sørensen, S. S., Jespersen, B., Kampmann, J., Rabinovich, G. A., Søndergaard, E., Nielsen, P. S. & D'Amore, F. A. (2014). Tumor microenvironmental features and outcome in post-transplant lymphoproliferative disorder. Poster session presented at ASH 2014 American Society of Hematology, San Francisco, United States.
Vajavaara, H., Ekeblad, F., Holte, H., Jorgensen, J., Leivonen, S.-K., Berglund, M., Kamper, P., Moller, H. J., D'Amore, F., Molin, D., Enblad, G., Ludvigsen, M., Glimelius, I. & Leppa, S. (2021). Prognostic impact of soluble CD163 in patients with diffuse large Bcell lymphoma. Haematologica, 106(9), 2502-2506. https://doi.org/10.3324/haematol.2020.278182
Sobrero, A., Muzzulini, C., d'Amore, F. A., Bogliolo, G., Massa, G., Ghio, R. & Pannacciulli, I. (1982). Activity of 4'-epi-doxorubicin on normal hematopoietic precursor cells in mice. Cancer Treatment Report, 66(12), 2061-70.
Snipsøyr, M. G., Wiggers, H., Knudsen, J. B., Ludvigsen, M., Poulsen, S. H., Petersen, E. & Honoré, B. (2013). Identification of putative, novel biomarkers for infective endocarditis by proteomic analysis. Poster session presented at 30th annual meeting of Nordic Society of Clinical Microbiology and Infectious Diseases, Aarhus, Denmark.
Smir, BN., Hauke, RJ., Bierman, PJ., Gross, TG., d'Amore, F. A., Anderson, JR. & Greiner, TG. (1996). Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders. Laboratory Investigation, 75((4)), 575-88.
Smir, BN., Hauke, RJ., Bierman, PJ., Gross, TG., d'Amore, F. A., Anderson, JR. & Greiner, TC. (1997). Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders. Laboratory Investigation, 76((3)), 439.
Shelton, V., Detroja, R., Liu, T., Isaev, K., Silva, A., Passerini, V., Bakhtiari, M., Calvente, L., Hong, M., He, M. Y., Modi, S., Hershenfeld, S. A., Ludvigsen, M., Madsen, C., Hamilton-Dutoit, S., d’Amore, F. A., Brodtkorb, M., Johnson, N. A., Baetz, T. ... Kridel, R. (2024). Identification of genetic subtypes in follicular lymphoma. Blood Cancer Journal, 14(1), Article 128. https://doi.org/10.1038/s41408-024-01111-w
Segel, E., Sørensen, B., D'Amore, F. A. & Hokland, P. (2010). Successful peripheral blood stem cell harvest in mobilization-refractory lymphoma patients. Bone Marrow Transplantation, 45(suppl. 2), 258.
Rostgaard, K., Hamilton-Dutoit, S., Lauridsen, K. L., Ottander, L., Plesner, T. L., Hollander, P., Brown, P., Sjö, L., Johansen, C., Kamper, P., Høgdall, E., d'Amore, F., Specht, L., Jarrett, R. F., McKay, J. D., Hutchings, M., Hjalgrim, L. L., Glimelius, I. & Hjalgrim, H. (2025). Epidemiological evidence for the role of puberty and immune senescence in Hodgkin lymphoma aetiology from 1992 Danish cases. International Journal of Cancer. Advance online publication. https://doi.org/10.1002/ijc.70305
Ristolainen, H., Kilpivaara, O., Kamper, P., Taskinen, M., Saarinen, S., Leppä, S., D'Amore, F. A. & Aaltonen, L. (2015). Identification of novel germline variants in early-onset familial classical Hodgkin lymphoma by exome sequencing. British Journal of Haematology, 170(3), 428-31.
Ristolainen, H., Kilpivaara, O., Kamper, P., Taskinen, M., Saarinen, S., Leppä, S., d'Amore, F. & Aaltonen, L. A. (2015). Identification of homozygous deletion in ACAN and other candidate variants in familial classical Hodgkin lymphoma by exome sequencing. British Journal of Haematology, 170(3), 428-431. https://doi.org/10.1111/bjh.13295
Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., Cavallin-Ståhl, E., Holte, H., Østerborg, A., Merup, M., Brown, P. D. N., Østenstad, B., Kuittinen, O., Erlanson, M., Fagerli, UM., Gadeberg, O., Sundström, C., Delabie, J., Ralfkier, E., Vornanen, M. & D'Amore, F. A. (2010). favorable outcome in ALK-negative anaplastic large-cell lymphoma following intensive induction chemotherapy and autologous stem cell transplantation (ASCT): a prospective study by the Nordic Lymphoma Group (NLG-T-01). Blood, 116(21).